A HEALTH ECONOMIC AND ENVIRONMENTAL EVALUATION OF SUBCUTANEOUS PERTUZUMAB/TRASTUZUMABVERSUS INTRAVENOUS PERTUZUMAB/TRASTUZUMAB FOR HER2-POSITIVE BREAST CANCER IN DENMARK (HEREAFTER)
Author(s)
Anders Davidsen, PharmD, PhD1, Andreas Fanoe, PharmD & Master in personalized medicine1, Marianne Botoft, PharmD1, Ulla Brix Tange, MD, PhD2, Ann Søegaard Knoop, MD, PhD2;
1Roche Pharmaceuticals A/S, Copenhagen, Denmark, 2Rigshospitalet, Copenhagen, Denmark
1Roche Pharmaceuticals A/S, Copenhagen, Denmark, 2Rigshospitalet, Copenhagen, Denmark
OBJECTIVES: Capacity is a challenge in Danish healthcare. Subcutaneous (SC) administration may offer a more time-efficient clinical setup while also providing benefits for patients and hospital personnel. This study analyzed potential cost, resource, and environmental savings of SC versus intravenous (IV) pertuzumab/trastuzumab (PT) in a Danish outpatient setting.
METHODS: Two outpatient scenarios (PT SC and PT IV) were modeled to compare total economic costs and time expenditure from hospital pharmacy preparation to patient discharge. Data were derived from Summary of Product Characteristics, the Danish health technology assessment cost analysis and regional payment data. Data and assumptions were validated by clinical experts
RESULTS: The analysis demonstrated substantial non-drug cost savings with SC administration compared to IV. Per patient course, savings amounted to €3,980 in adjuvant setting (17 treatments) and €2,661 in 1st line setting (11.6 treatments). In terms of hospital resource utilization, extrapolating treatment to one year revealed a yearly HCP time expenditure of 8.7 hours for SC versus 104.4 hours for IV per patient. At a national level, based on the annual incidence of HER2-positive breast cancer, the total estimated annual HCP burden was 995.5 hours for PT SC compared with 11,970 hours for PT IV. This difference of 10,975 hours indicates that the IV workload is a factor of 12 higher than SC, corresponding to approximately 6 full-time equivalents annually within the Danish healthcare sector. Additionally there is up to a 65% reduction in vials and utensils with PT SC compared to PT IV, resulting in a reduced environmental impact.
CONCLUSIONS: Implementing SC PT in a hospital outpatient setting has the potential to free up resources and increase capacity by reducing the number of hours spent by HCPs, while simultaneously lowering the environmental and economic costs.
METHODS: Two outpatient scenarios (PT SC and PT IV) were modeled to compare total economic costs and time expenditure from hospital pharmacy preparation to patient discharge. Data were derived from Summary of Product Characteristics, the Danish health technology assessment cost analysis and regional payment data. Data and assumptions were validated by clinical experts
RESULTS: The analysis demonstrated substantial non-drug cost savings with SC administration compared to IV. Per patient course, savings amounted to €3,980 in adjuvant setting (17 treatments) and €2,661 in 1st line setting (11.6 treatments). In terms of hospital resource utilization, extrapolating treatment to one year revealed a yearly HCP time expenditure of 8.7 hours for SC versus 104.4 hours for IV per patient. At a national level, based on the annual incidence of HER2-positive breast cancer, the total estimated annual HCP burden was 995.5 hours for PT SC compared with 11,970 hours for PT IV. This difference of 10,975 hours indicates that the IV workload is a factor of 12 higher than SC, corresponding to approximately 6 full-time equivalents annually within the Danish healthcare sector. Additionally there is up to a 65% reduction in vials and utensils with PT SC compared to PT IV, resulting in a reduced environmental impact.
CONCLUSIONS: Implementing SC PT in a hospital outpatient setting has the potential to free up resources and increase capacity by reducing the number of hours spent by HCPs, while simultaneously lowering the environmental and economic costs.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EE460
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
SDC: Oncology